Caris Raises 2026 Revenue Guidance to $1.03 Billion to $1.04 Billion as Q2 Revenue Rises 45%
Caris Life Sciences reported second-quarter 2026 revenue of $263.7 million, up 45% from $181.4 million a year earlier, and narrowed its net loss to $0.6 million from $71.8 million. The company raised its full-year 2026 revenue guidance to $1.03 billion to $1.04 billion, which it says represents growth of 27% to 28%, giving shareholders a higher revenue outlook.
Key points
- Q2 2026 total revenue was $263.7 million, up $82.3 million, or 45%, from the prior year period.
- Net loss was $0.6 million, or $0.00 per share, compared with a net loss of $71.8 million, or $7.97 per share, a year earlier.
- Adjusted EBITDA was $55.7 million, and free cash flow was $6.4 million for the quarter.
- Full-year 2026 revenue guidance was raised to $1.03 billion to $1.04 billion; about $82.1 million remains under the existing share repurchase authorization.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.